DIVISLAB Stock Overview
Engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Divi's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹4,826.95 |
| 52 Week High | ₹5,010.00 |
| 52 Week Low | ₹3,295.30 |
| Beta | 0.37 |
| 11 Month Change | 4.26% |
| 3 Month Change | 23.41% |
| 1 Year Change | 23.43% |
| 33 Year Change | -1.61% |
| 5 Year Change | 189.92% |
| Change since IPO | 54,673.90% |
Recent News & Updates
Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts
Aug 06
The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts
Jul 19Recent updates
Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts
Aug 06The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts
Jul 19Shareholders Should Be Pleased With Divi's Laboratories Limited's (NSE:DIVISLAB) Price
Apr 19Divi's Laboratories Limited (NSE:DIVISLAB) Not Flying Under The Radar
Dec 27Divi's Laboratories (NSE:DIVISLAB) Will Pay A Dividend Of ₹30.00
Aug 04Divi's Laboratories (NSE:DIVISLAB) Will Pay A Dividend Of ₹30.00
Jul 20Divi's Laboratories (NSE:DIVISLAB) Has Announced A Dividend Of ₹30.00
Jul 06Is Now The Time To Put Divi's Laboratories (NSE:DIVISLAB) On Your Watchlist?
Nov 08Divi's Laboratories (NSE:DIVISLAB) Is Increasing Its Dividend To ₹30.00
Aug 04Divi's Laboratories' (NSE:DIVISLAB) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 21Divi's Laboratories (NSE:DIVISLAB) Will Pay A Larger Dividend Than Last Year At ₹30.00
Jul 07Here's Why We Think Divi's Laboratories (NSE:DIVISLAB) Might Deserve Your Attention Today
Jul 03Does Divi's Laboratories (NSE:DIVISLAB) Deserve A Spot On Your Watchlist?
Apr 03Should You Be Adding Divi's Laboratories (NSE:DIVISLAB) To Your Watchlist Today?
Dec 23With EPS Growth And More, Divi's Laboratories (NSE:DIVISLAB) Is Interesting
Sep 02Here's Why We Think Divi's Laboratories (NSE:DIVISLAB) Is Well Worth Watching
Mar 25Do Institutions Own Divi's Laboratories Limited (NSE:DIVISLAB) Shares?
Mar 10Shareholder Returns
| DIVISLAB | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -2.0% | -2.2% | -4.0% |
| 1Y | 23.4% | 17.4% | 40.0% |
Return vs Industry: DIVISLAB exceeded the Indian Life Sciences industry which returned 17.4% over the past year.
Return vs Market: DIVISLAB underperformed the Indian Market which returned 40% over the past year.
Price Volatility
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 3.7% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: DIVISLAB has not had significant price volatility in the past 3 months.
Volatility Over Time: DIVISLAB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 9,741 | Kiran Divi | www.divislabs.com |
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products.
Divi's Laboratories Limited Fundamentals Summary
| DIVISLAB fundamental statistics | |
|---|---|
| Market cap | ₹1.28t |
| Earnings (TTM) | ₹16.74b |
| Revenue (TTM) | ₹81.85b |
76.5x
P/E Ratio15.7x
P/S RatioIs DIVISLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIVISLAB income statement (TTM) | |
|---|---|
| Revenue | ₹81.85b |
| Cost of Revenue | ₹35.17b |
| Gross Profit | ₹46.68b |
| Other Expenses | ₹29.94b |
| Earnings | ₹16.74b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 63.06 |
| Gross Margin | 57.03% |
| Net Profit Margin | 20.45% |
| Debt/Equity Ratio | 0.02% |
How did DIVISLAB perform over the long term?
See historical performance and comparison